Robert Hazlett
Stock Analyst at BTIG
(1.31)
# 3,581
Out of 5,058 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.56 | +331.65% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $59.40 | +1.01% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.65 | +751.06% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $3.45 | +28,885.51% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $146.52 | -33.11% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $9.82 | +511.00% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $5.49 | +1,047.54% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $10.43 | +178.04% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.04 | +2,497,258.56% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.62 | +271.52% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $13.82 | +30.25% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.56
Upside: +331.65%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $59.40
Upside: +1.01%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.65
Upside: +751.06%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $3.45
Upside: +28,885.51%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $146.52
Upside: -33.11%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $9.82
Upside: +511.00%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $5.49
Upside: +1,047.54%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $10.43
Upside: +178.04%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.04
Upside: +2,497,258.56%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.62
Upside: +271.52%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $13.82
Upside: +30.25%